Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04024800
Title Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14)
Acronym NSABP FB-14
Recruitment Unknown status
Gender female
Phase Phase II
Variant Requirements No
Sponsors Antigen Express, Inc
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.